James E Flynn Insider Trading $EMLR Talon Therapeutics, Inc.
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
James E Flynn in Talon Therapeutics, Inc.
Trading Symbol: EMLRIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of James E Flynn: Director
Holdings: 0 shares
Latest Transaction: Jul 18 2013
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of James E Flynn in Talon Therapeutics, Inc.
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Sep 28 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 1,528 | 1,528 | 604,950 | 606.5 K to 605 K (-0.25 %) |
Sep 28 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 849 | 849 | 323,343 | 324.2 K to 323.3 K (-0.26 %) |
Sep 26 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 4,843 | 4,746 | 1,251,262 | 1.3 M to 1.3 M (-0.39 %) |
Sep 26 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 3,007 | 2,947 | 776,720 | 779.7 K to 776.7 K (-0.39 %) |
Sep 26 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 2,342 | 2,295 | 606,478 | 608.8 K to 606.5 K (-0.38 %) |
Sep 26 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.98 | 1,301 | 1,275 | 324,192 | 325.5 K to 324.2 K (-0.40 %) |
Sep 21 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 10,746 | 10,746 | 1,256,106 | 1.3 M to 1.3 M (-0.85 %) |
Sep 21 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 6,671 | 6,671 | 779,727 | 786.4 K to 779.7 K (-0.85 %) |
Sep 21 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 5,196 | 5,196 | 608,820 | 614 K to 608.8 K (-0.85 %) |
Sep 21 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 2,886 | 2,886 | 325,493 | 328.4 K to 325.5 K (-0.88 %) |
Sep 21 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.05 | 13,907 | 14,602 | 1,266,852 | 1.3 M to 1.3 M (-1.09 %) |
Sep 21 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.05 | 8,633 | 9,065 | 786,398 | 795 K to 786.4 K (-1.09 %) |
Sep 21 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.05 | 6,725 | 7,061 | 614,016 | 620.7 K to 614 K (-1.08 %) |
Sep 21 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.05 | 3,735 | 3,922 | 328,379 | 332.1 K to 328.4 K (-1.12 %) |
Sep 02 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.97 | 36,032 | 34,951 | 1,280,759 | 1.3 M to 1.3 M (-2.74 %) |
Sep 02 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.97 | 22,367 | 21,696 | 795,031 | 817.4 K to 795 K (-2.74 %) |
Sep 02 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.97 | 17,423 | 16,900 | 620,741 | 638.2 K to 620.7 K (-2.73 %) |
Sep 02 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.97 | 9,678 | 9,388 | 332,114 | 341.8 K to 332.1 K (-2.83 %) |
Jul 18 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 5,563 | 5,507 | 1,316,791 | 1.3 M to 1.3 M (-0.42 %) |
Jul 18 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 3,453 | 3,418 | 817,398 | 820.9 K to 817.4 K (-0.42 %) |
Jul 18 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 2,690 | 2,663 | 638,164 | 640.9 K to 638.2 K (-0.42 %) |
Jul 18 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 1,494 | 1,479 | 341,792 | 343.3 K to 341.8 K (-0.44 %) |
Jun 27 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.06 | 6,531 | 6,923 | 1,322,354 | 1.3 M to 1.3 M (-0.49 %) |
Jun 27 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.06 | 4,055 | 4,298 | 820,851 | 824.9 K to 820.9 K (-0.49 %) |
Jun 27 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.06 | 3,159 | 3,349 | 640,854 | 644 K to 640.9 K (-0.49 %) |
Jun 27 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.06 | 1,755 | 1,860 | 343,286 | 345 K to 343.3 K (-0.51 %) |
Jun 27 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.07 | 54,785 | 58,620 | 1,328,885 | 1.4 M to 1.3 M (-3.96 %) |
Jun 27 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.07 | 34,008 | 36,389 | 824,906 | 858.9 K to 824.9 K (-3.96 %) |
Jun 27 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.07 | 26,491 | 28,345 | 644,013 | 670.5 K to 644 K (-3.95 %) |
Jun 27 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.07 | 14,716 | 15,746 | 345,041 | 359.8 K to 345 K (-4.09 %) |
Jun 27 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.94 | 42,142 | 39,613 | 1,383,670 | 1.4 M to 1.4 M (-2.96 %) |
Jun 27 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.94 | 26,160 | 24,590 | 858,914 | 885.1 K to 858.9 K (-2.96 %) |
Jun 27 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.07 | 20,378 | 21,804 | 670,504 | 690.9 K to 670.5 K (-2.95 %) |
Jun 27 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.07 | 11,320 | 12,112 | 359,757 | 371.1 K to 359.8 K (-3.05 %) |
Jun 15 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.02 | 14,724 | 15,018 | 1,425,812 | 1.4 M to 1.4 M (-1.02 %) |
Jun 15 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.02 | 9,139 | 9,322 | 885,074 | 894.2 K to 885.1 K (-1.02 %) |
Jun 15 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.02 | 5,685 | 5,799 | 690,882 | 696.6 K to 690.9 K (-0.82 %) |
Jun 15 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.02 | 3,633 | 3,706 | 371,077 | 374.7 K to 371.1 K (-0.97 %) |
Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.03 | 24,398 | 25,130 | 1,440,536 | 1.5 M to 1.4 M (-1.67 %) |
Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.03 | 15,145 | 15,599 | 894,213 | 909.4 K to 894.2 K (-1.67 %) |
Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.03 | 9,429 | 9,712 | 696,597 | 706 K to 696.6 K (-1.34 %) |
Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.03 | 6,028 | 6,209 | 374,710 | 380.7 K to 374.7 K (-1.58 %) |
Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.02 | 19,081 | 19,463 | 1,464,934 | 1.5 M to 1.5 M (-1.29 %) |
Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.02 | 11,844 | 12,081 | 909,358 | 921.2 K to 909.4 K (-1.29 %) |
Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.02 | 7,367 | 7,514 | 705,996 | 713.4 K to 706 K (-1.03 %) |
Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.02 | 4,708 | 4,802 | 380,738 | 385.4 K to 380.7 K (-1.22 %) |
Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 4,052 | 4,093 | 1,484,015 | 1.5 M to 1.5 M (-0.27 %) |
Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 2,514 | 2,539 | 921,202 | 923.7 K to 921.2 K (-0.27 %) |
Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 1,564 | 1,580 | 713,363 | 714.9 K to 713.4 K (-0.22 %) |
Jun 07 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 1,000 | 1,010 | 385,446 | 386.4 K to 385.4 K (-0.26 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 124,688 | 124,688 | 1,573,653 | 1.7 M to 1.6 M (-7.34 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 77,399 | 77,399 | 976,841 | 1.1 M to 976.8 K (-7.34 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 48,135 | 48,135 | 747,966 | 796.1 K to 748 K (-6.05 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 30,779 | 30,779 | 407,568 | 438.3 K to 407.6 K (-7.02 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 7,192 | 7,192 | 1,698,341 | 1.7 M to 1.7 M (-0.42 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 4,464 | 4,464 | 1,054,240 | 1.1 M to 1.1 M (-0.42 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 2,777 | 2,777 | 796,101 | 798.9 K to 796.1 K (-0.35 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 1,774 | 1,774 | 438,347 | 440.1 K to 438.3 K (-0.40 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 21,741 | 21,524 | 1,705,533 | 1.7 M to 1.7 M (-1.26 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 13,495 | 13,360 | 1,058,704 | 1.1 M to 1.1 M (-1.26 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 4,694 | 4,694 | 798,878 | 803.6 K to 798.9 K (-0.58 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 3,000 | 3,000 | 440,121 | 443.1 K to 440.1 K (-0.68 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 12,159 | 12,159 | 1,727,274 | 1.7 M to 1.7 M (-0.70 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.00 | 7,547 | 7,547 | 1,072,199 | 1.1 M to 1.1 M (-0.70 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 8,394 | 8,310 | 803,572 | 812 K to 803.6 K (-1.03 %) |
May 24 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 5,365 | 5,311 | 443,121 | 448.5 K to 443.1 K (-1.20 %) |
May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 11,667 | 11,550 | 1,488,067 | 1.5 M to 1.5 M (-0.78 %) |
May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 7,242 | 7,170 | 923,716 | 931 K to 923.7 K (-0.78 %) |
May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 4,504 | 4,459 | 714,927 | 719.4 K to 714.9 K (-0.63 %) |
May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 2,879 | 2,850 | 386,446 | 389.3 K to 386.4 K (-0.74 %) |
May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 19,836 | 19,638 | 1,499,734 | 1.5 M to 1.5 M (-1.31 %) |
May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 12,312 | 12,189 | 930,958 | 943.3 K to 931 K (-1.31 %) |
May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 7,657 | 7,580 | 719,431 | 727.1 K to 719.4 K (-1.05 %) |
May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.99 | 4,895 | 4,846 | 389,325 | 394.2 K to 389.3 K (-1.24 %) |
May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 54,083 | 54,624 | 1,519,570 | 1.6 M to 1.5 M (-3.44 %) |
May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 33,571 | 33,907 | 943,270 | 976.8 K to 943.3 K (-3.44 %) |
May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 20,878 | 21,087 | 727,088 | 748 K to 727.1 K (-2.79 %) |
May 31 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.01 | 13,348 | 13,481 | 394,220 | 407.6 K to 394.2 K (-3.28 %) |
May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 23,092 | 25,632 | 1,739,433 | 1.8 M to 1.7 M (-1.31 %) |
May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 14,334 | 15,911 | 1,079,746 | 1.1 M to 1.1 M (-1.31 %) |
May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 8,915 | 9,896 | 811,966 | 820.9 K to 812 K (-1.09 %) |
May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 5,698 | 6,325 | 448,486 | 454.2 K to 448.5 K (-1.25 %) |
May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 34,061 | 37,808 | 1,762,525 | 1.8 M to 1.8 M (-1.90 %) |
May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 21,143 | 23,469 | 1,094,080 | 1.1 M to 1.1 M (-1.90 %) |
May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 13,149 | 14,595 | 820,881 | 834 K to 820.9 K (-1.58 %) |
May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.11 | 8,406 | 9,331 | 454,184 | 462.6 K to 454.2 K (-1.82 %) |
May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.12 | 74,913 | 83,903 | 1,796,586 | 1.9 M to 1.8 M (-4.00 %) |
May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.12 | 46,501 | 52,081 | 1,115,223 | 1.2 M to 1.1 M (-4.00 %) |
May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.12 | 28,919 | 32,389 | 834,030 | 862.9 K to 834 K (-3.35 %) |
May 19 2011 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 1.12 | 18,489 | 20,708 | 462,590 | 481.1 K to 462.6 K (-3.84 %) |
Sep 14 2010 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.74 | 135 | 99 | 4,448 | |
Sep 14 2010 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.74 | 73 | 54 | 2,426 | |
Sep 14 2010 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.74 | 646 | 475 | 21,213 | |
Sep 14 2010 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.74 | 401 | 295 | 13,168 | |
Jun 09 2010 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | P | 0.13 | 4,313 | 556 | 4,313 | |
Jun 09 2010 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | P | 0.13 | 2,353 | 303 | 2,353 | |
Jun 09 2010 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | P | 0.13 | 20,567 | 2,649 | 20,567 | |
Jun 09 2010 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | P | 0.13 | 12,767 | 1,644 | 12,767 |